It has been reported that metastasis-associated gene 1 （Mta1） is overexpressed in many malignant tumors with high metastatic potential. In addition, some studies indicated that MTA1 participated in invasion, metasta...It has been reported that metastasis-associated gene 1 （Mta1） is overexpressed in many malignant tumors with high metastatic potential. In addition, some studies indicated that MTA1 participated in invasion, metastasis, and survival of cancer cells by regulating cell migration, adhesion and proliferation. But the role of MTA1 is unclear in vitro in the development of cervical cancer cells. This study investigated whether and how MTA1 mediated cell proliferation, migration, invasion and adhesion in cervical cancer. MTA1 expression level was detected by Western blot in two cervical cancer cell lines of different invasion potentials. The effects of MTA1 expression on SiHa cell apoptosis, cycle, proliferation, migration, invasion and adhesion were tested by flow cytometry, MTT, wound-healing assay, Transwell assay and adhesion assay, respectively. The expression levels of p53, E-cadherin, and β-catenin activity were evaluated in untreated and treated cells. The results showed that MTA1 protein expression was significantly higher in SiHa than in HeLa, which was correlated well with the potential of migration and invasion in both cell lines. Furthermore, the cell invasion, migration and adhesion capabilities were decreased after inhibition of MTA1 expression mediated by Mta1-siRNA transfection in SiHa. However, no significant differences were found in cell apoptosis, cycle, and proliferation. In addition, E-cadherin and p53 protein levels were significantly up-regulated, while β-catenin was significantly down-regulated in SiHa transfected with the siRNA. These results demonstrated that MTA1 played an important role in the migration and invasion of cervical cancer cells. It was speculated that the decreased migration and invasion capability by inhibiting the MTA1 expression in the SiHa cell line may be mediated through the altered expression of p53, and E-cadherin/β-catenin complex. MTA1 could serve as a potential therapeutic target in cervical cancer.展开更多
BACKGROUND Peutz-Jeghers syndrome(PJS)is a rare autosomal dominant disorder,and female patients may develop gynecologic tumours.The prognosis for such patients is poor and the specific pathogenesis remains uncertain.T...BACKGROUND Peutz-Jeghers syndrome(PJS)is a rare autosomal dominant disorder,and female patients may develop gynecologic tumours.The prognosis for such patients is poor and the specific pathogenesis remains uncertain.Therefore,there are currently no uniform treatment options.CASE SUMMARY Herein,we introduce the case of a 45-year-old female who was diagnosed with PJS for 45 years and cervical cancer for 3 years.Postoperative pathological examination showed metastases in the right external iliac lymph nodes.The patient was initially treated with a combination of doxorubicin and carboplatin chemotherapy and pelvic magnetic resonance showed that the metastases had grown.Subsequently,we performed whole exome sequencing in this patient and identified the relevant causative gene.In addition to the chemotherapy regimen,sindilizumab was administered and the patient was followed up.After 4 cycles of treatment,the metastases were substantially reduced and were not enlarged after six months of follow-up.This case report suggests that patients with PJS combined with cervical cancer may have a sustained response to immunecombination chemotherapy regimens.CONCLUSION Clinicians should be aware of the importance of immunotherapy in patients with PJS combined with advanced cervical cancer.展开更多
BACKGROUND The prognosis for patients with advanced metastatic cervix cancer(MCC)is poor,and this disease continues to pose a considerable therapeutic challenge.Despite the administration of first-line regimens consis...BACKGROUND The prognosis for patients with advanced metastatic cervix cancer(MCC)is poor,and this disease continues to pose a considerable therapeutic challenge.Despite the administration of first-line regimens consisting of cisplatin,paclitaxel,and bevacizumab,survival rates for patients with metastasis remain poor.The emergence of bispecific antibodies(BsAbs)offers a novel treatment option for patients diagnosed with MCC.CASE SUMMARY In this report,we present a patient with MCC who was treated with cadonilimab monotherapy at a dose of 6 mg/kg every two weeks after chemotherapy was proven to be intolerable.The patient exhibited a sustained complete response for a duration of 6 months,demonstrating an optimistic outlook.CONCLUSION This case illustrates the considerable efficacy of cadonilimab for treating advanced MCC.Therefore,BsAb therapy is a promising strategy for effectively treating patients with advanced MCC and should be considered as an option when patients are intolerant to standard chemotherapy.展开更多
目的:分析热休克蛋白家族H(Hsp110)成员1[heat shock protein family H(Hsp110)member 1,HSPH1]在宫颈癌组织中的表达及其与预后的相关性。方法:收集2018年2月至2021年1月首次确诊的60例宫颈癌患者的癌组织和相邻非癌组织。通过qRT-PCR...目的:分析热休克蛋白家族H(Hsp110)成员1[heat shock protein family H(Hsp110)member 1,HSPH1]在宫颈癌组织中的表达及其与预后的相关性。方法:收集2018年2月至2021年1月首次确诊的60例宫颈癌患者的癌组织和相邻非癌组织。通过qRT-PCR检测HSPH1表达,分析其与肿瘤标志物、宫颈癌病理特征之间的关系,并通过Cox回归模型确定3年生存的独立预后因子。利用时间依赖性受试者工作特征(ROC)曲线评估HSPH1预测1年、2年和3年生存的临床价值,并通过外部数据库和细胞实验验证结果。结果:HSPH1在临床样本和GSE29570数据库宫颈癌组织中均呈高表达(P<0.05),且与CA125、CA19-9、CEA和SCCA呈正相关(均r>0,P<0.05)。高表达组(≥1.57)肿瘤大小≥4 cm、FIGOⅢ~Ⅳ期、淋巴结转移及淋巴血管空间侵犯比例均高于低表达组(P<0.05)。TCGA数据库和临床样本分析显示,高表达组患者生存率显著低于低表达组(P<0.01)。多因素Cox回归分析显示,HSPH1<1.57(HR=0.299,P=0.039)和无淋巴结转移(HR=0.245,P=0.003)是独立预后因子。HSPH1预测1年、2年和3年生存的曲线下面积分别为0.82、0.85和0.88。结论:HSPH1在宫颈癌组织中的高表达与患者较差的预后之间存在显著相关,HSPH1可作为宫颈癌预后评估和治疗靶点的潜在生物标志物。展开更多
基金supported by grants from the Major State Basic Research Development Program of China (973 Program,No. 2009CB521808)the National Natural Sciences Foundation of China (No. 30700895)
文摘It has been reported that metastasis-associated gene 1 （Mta1） is overexpressed in many malignant tumors with high metastatic potential. In addition, some studies indicated that MTA1 participated in invasion, metastasis, and survival of cancer cells by regulating cell migration, adhesion and proliferation. But the role of MTA1 is unclear in vitro in the development of cervical cancer cells. This study investigated whether and how MTA1 mediated cell proliferation, migration, invasion and adhesion in cervical cancer. MTA1 expression level was detected by Western blot in two cervical cancer cell lines of different invasion potentials. The effects of MTA1 expression on SiHa cell apoptosis, cycle, proliferation, migration, invasion and adhesion were tested by flow cytometry, MTT, wound-healing assay, Transwell assay and adhesion assay, respectively. The expression levels of p53, E-cadherin, and β-catenin activity were evaluated in untreated and treated cells. The results showed that MTA1 protein expression was significantly higher in SiHa than in HeLa, which was correlated well with the potential of migration and invasion in both cell lines. Furthermore, the cell invasion, migration and adhesion capabilities were decreased after inhibition of MTA1 expression mediated by Mta1-siRNA transfection in SiHa. However, no significant differences were found in cell apoptosis, cycle, and proliferation. In addition, E-cadherin and p53 protein levels were significantly up-regulated, while β-catenin was significantly down-regulated in SiHa transfected with the siRNA. These results demonstrated that MTA1 played an important role in the migration and invasion of cervical cancer cells. It was speculated that the decreased migration and invasion capability by inhibiting the MTA1 expression in the SiHa cell line may be mediated through the altered expression of p53, and E-cadherin/β-catenin complex. MTA1 could serve as a potential therapeutic target in cervical cancer.
文摘BACKGROUND Peutz-Jeghers syndrome(PJS)is a rare autosomal dominant disorder,and female patients may develop gynecologic tumours.The prognosis for such patients is poor and the specific pathogenesis remains uncertain.Therefore,there are currently no uniform treatment options.CASE SUMMARY Herein,we introduce the case of a 45-year-old female who was diagnosed with PJS for 45 years and cervical cancer for 3 years.Postoperative pathological examination showed metastases in the right external iliac lymph nodes.The patient was initially treated with a combination of doxorubicin and carboplatin chemotherapy and pelvic magnetic resonance showed that the metastases had grown.Subsequently,we performed whole exome sequencing in this patient and identified the relevant causative gene.In addition to the chemotherapy regimen,sindilizumab was administered and the patient was followed up.After 4 cycles of treatment,the metastases were substantially reduced and were not enlarged after six months of follow-up.This case report suggests that patients with PJS combined with cervical cancer may have a sustained response to immunecombination chemotherapy regimens.CONCLUSION Clinicians should be aware of the importance of immunotherapy in patients with PJS combined with advanced cervical cancer.
文摘BACKGROUND The prognosis for patients with advanced metastatic cervix cancer(MCC)is poor,and this disease continues to pose a considerable therapeutic challenge.Despite the administration of first-line regimens consisting of cisplatin,paclitaxel,and bevacizumab,survival rates for patients with metastasis remain poor.The emergence of bispecific antibodies(BsAbs)offers a novel treatment option for patients diagnosed with MCC.CASE SUMMARY In this report,we present a patient with MCC who was treated with cadonilimab monotherapy at a dose of 6 mg/kg every two weeks after chemotherapy was proven to be intolerable.The patient exhibited a sustained complete response for a duration of 6 months,demonstrating an optimistic outlook.CONCLUSION This case illustrates the considerable efficacy of cadonilimab for treating advanced MCC.Therefore,BsAb therapy is a promising strategy for effectively treating patients with advanced MCC and should be considered as an option when patients are intolerant to standard chemotherapy.
文摘目的:分析热休克蛋白家族H(Hsp110)成员1[heat shock protein family H(Hsp110)member 1,HSPH1]在宫颈癌组织中的表达及其与预后的相关性。方法:收集2018年2月至2021年1月首次确诊的60例宫颈癌患者的癌组织和相邻非癌组织。通过qRT-PCR检测HSPH1表达,分析其与肿瘤标志物、宫颈癌病理特征之间的关系,并通过Cox回归模型确定3年生存的独立预后因子。利用时间依赖性受试者工作特征(ROC)曲线评估HSPH1预测1年、2年和3年生存的临床价值,并通过外部数据库和细胞实验验证结果。结果:HSPH1在临床样本和GSE29570数据库宫颈癌组织中均呈高表达(P<0.05),且与CA125、CA19-9、CEA和SCCA呈正相关(均r>0,P<0.05)。高表达组(≥1.57)肿瘤大小≥4 cm、FIGOⅢ~Ⅳ期、淋巴结转移及淋巴血管空间侵犯比例均高于低表达组(P<0.05)。TCGA数据库和临床样本分析显示,高表达组患者生存率显著低于低表达组(P<0.01)。多因素Cox回归分析显示,HSPH1<1.57(HR=0.299,P=0.039)和无淋巴结转移(HR=0.245,P=0.003)是独立预后因子。HSPH1预测1年、2年和3年生存的曲线下面积分别为0.82、0.85和0.88。结论:HSPH1在宫颈癌组织中的高表达与患者较差的预后之间存在显著相关,HSPH1可作为宫颈癌预后评估和治疗靶点的潜在生物标志物。
